Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Journal of Dental Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ohno, S.
Right arrow Articles by Tanne, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohno, S.
Right arrow Articles by Tanne, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

RGD-CAP (βig-h3) Exerts a Negative Regulatory Function on Mineralization in the Human Periodontal Ligament

S. Ohno1,*, T. Doi1, K. Fujimoto2, C. Ijuin1, N. Tanaka1, K. Tanimoto1, K. Honda1, M. Nakahara1, Y. Kato2 and K. Tanne1

1 Departments of Orthodontics and
2 Biochemistry, Hiroshima University Faculty of Dentistry, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan;


Figure 1
View larger version (109K):
[in this window]
[in a new window]

 
Figure 1. Expression of RGD-CAP in the PDL. Western blot analysis of RGD-CAP in human PDL in the presence of β-mercaptoethanol (β-ME; 0-5.0%).

 

Figure 2
View larger version (30K):
[in this window]
[in a new window]

 
Figure 2. RGD-CAP mRNA level and ALP activity cultured PDL cells. After the PDL cells became confluent, the cells maintained in Medium A were treated with 10–8 M dexamethasone (Dex) or 10–8 M 1{alpha},25-dihydroxyvitamin D3 (vitamin D3) for 0-11 days. The rate of increase in RGD-CAP mRNA expression determined by real-time PCR is shown as a bar. The dotted line indicates the level of RGD-CAP mRNA on day 0. Levels of ALP activity in these cultures were evaluated by measurement of the absorbance at 405 nm and are shown as lines. Values are averages ± SD of triplicate cultures.

 

Figure 3
View larger version (39K):
[in this window]
[in a new window]

 
Figure 3. Effects of RGD-CAP on mineralization of PDL cells. (A) The PDL cells were seeded confluently on the 35-mm dishes coated with recombinant RGD-CAP (20 µg/mL), maintained in Medium A for 1-5 days. ALP activity was measured following the method described in MATERIALS & METHODS. Values are averages ± SD of triplicate cultures. (B,C) A 20-µg/mL quantity of recombinant RGD-CAP in the solution buffer (PBS containing 4 M urea) or solution buffer (control) was added to the mineralizing medium (MM) of PDL cell cultures every 2 days. Total RNA was extracted on day 11, and RT-PCR was performed. Ethidium bromide staining pattern of PCR products of type I collagen (Col I), bone sialoprotein (BSP), and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) was shown in panel (B). We determined the relative mRNA expression of Col I or BSP by dividing the densitometric value of RT-PCR products of each transcript by that of G3PDH. Alizarin red staining was performed for the cells cultured on day 21, and the number of bone nodules was counted (C). **p < 0.01.

 

Journal of Dental Research, Vol. 81, No. 12, 822-825 (2002)
DOI: 10.1177/154405910208101205


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?